<?xml version="1.0" encoding="UTF-8"?>
<p>A recent non-controlled prospective trial (IRCT20151227025726N12) evaluated the subcutaneous use of INF beta-1a in combination therapy with hydroxychloroquine and lopinavir/ritonavir. The early results showed a positive response in terms of symptomatology (mainly fever) resolution, virologic clearance, and hospitalization period [
 <xref rid="B154-jcm-09-02084" ref-type="bibr">154</xref>]. However, some authors debate the need to address the clear differences concerning s.c versus i.v. administration, as these routes significantly influence the bioavailability of the drug and, consequently, the therapeutic response [
 <xref rid="B151-jcm-09-02084" ref-type="bibr">151</xref>].
</p>
